about
Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptidesAn efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinomaInvariant NKT cells sustain specific B cell responses and memory.Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells.A novel self-lipid antigen targets human T cells against CD1c(+) leukemiasMAGE-1 gene product is a cytoplasmic protein.Intracellular modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activationFine tuning by human CD1e of lipid-specific immune responses.A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse ModelInvariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantation.Alliance Against Cancer, the network of Italian cancer centers bridging research and careMelanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolutionFollicular helper NKT cells induce limited B cell responses and germinal center formation in the absence of CD4(+) T cell help.Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells.miR-17∼92 family clusters control iNKT cell ontogenesis via modulation of TGF-β signaling.Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies.On the use of donor-derived iNKT cells for adoptive immunotherapy to prevent leukemia recurrence in pediatric recipients of HLA haploidentical HSCT for hematological malignancies.Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation.A family of trans-acting factors with distinct regulatory functions control expression of MHC class II genes.iNKT-cell help to B cells: a cooperative job between innate and adaptive immune responses.Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer.Group 1 CD1-restricted T cells and the pathophysiological implications of self-lipid antigen recognition.Of self-lipids, CD1-restricted T cells, and contact sensitization.Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4.Harnessing the CD1 restricted T cell response for leukemia adoptive immunotherapy.The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides.Targeting leukemia by CD1c-restricted T cells specific for a novel lipid antigen.Serological immunoreactivity against colon cancer proteome varies upon disease progression.Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop.Dual receptor T-cells. Implications for alloreactivity and autoimmunity.T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genesA single amino acid substitution in the Ak molecule fortuitously provokes an alloresponse.In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.Superantigens interact with MHC class II molecules outside of the antigen groove.Guidelines for the use of flow cytometry and cell sorting in immunological studies.The Wiskott-Aldrich syndrome protein is required for iNKT cell maturation and function.Functional education of invariant NKT cells by dendritic cell tuning of SHP-1.
P50
Q25257170-2FE37F97-DD41-42A6-81CC-3A89B8A638FFQ28749871-02469079-A958-4F56-8247-BF652E3B98F2Q30479030-88DCAA6D-D704-45F0-AB23-19C36D770087Q33318487-F039D193-9886-4640-B58A-EE9B8B3AAF7AQ33523809-9AB05C52-2170-4B89-BF66-55026EC07346Q33826848-44274832-CBA3-43FD-BAF2-C353D25CD1B0Q34323516-DA1FAF28-31E8-4196-9BC3-E62DA4B287BEQ35037006-CE9F309E-7EC1-4EFD-B4B9-501E46D63233Q35180802-F7C2190F-A452-4951-BB59-124CC3EEB6A0Q35931493-B1A651FD-3797-4C03-BB49-F728EBDDF046Q36057428-E887B351-F6AC-4453-9BFA-B241564C6AEDQ36292686-8B05E65F-968F-4168-BC7D-D899FE1998E8Q36367846-EEAD90E4-1CBD-4484-BD5E-E2C3B1E98004Q36404242-D2F42C34-A04C-40DC-ABC0-F745190F7920Q36573926-621C3E34-153B-428E-8C9B-7266F14039FBQ36702144-96CD3962-9EB0-4B62-B500-5B5F3D01A208Q37534350-0358FD44-CCBC-42EC-BB6C-D62B77CA646FQ37737788-2AFB8394-C80F-4858-858C-8BD71B9BDB98Q37824066-69FC0FB8-A00A-4DF9-A66F-43BE7A51B9FEQ37933826-A934E9FD-EB19-47A1-B40A-1313EDC20673Q38142274-1AC2C667-7C8C-46D9-8C32-F7BAD5B62E87Q38208261-6D9D9FB8-6488-4F9C-A717-C026BEB9C592Q38244094-7ED9F763-7670-418A-B3D2-B7F26D4B3BC4Q38619546-AA3941A0-06F0-400B-8C0D-EB71D6A8DBB1Q38687053-6D6AA7E3-16A4-4472-BE89-E7677C2614C5Q39054708-C74A45CC-D189-4C95-9A5A-E5A155A894DAQ39437723-5294F076-6C1E-4DB4-BCB1-406CF25E3D8DQ39725034-933292A7-70CF-449D-98F1-31892FBD4A3BQ39835296-2DDF2D19-CDFE-451D-9CCB-FC644ACDB8A7Q40027849-B1AB350E-D426-4CBA-98C3-D734C15226C5Q40229112-4488E5AA-B7B5-452A-8877-1E129B3CCE78Q40364593-CDDD92A0-E048-4FDC-8F42-5AF319AF349FQ40465770-D19AC42A-55E8-4350-8E25-B55C5A359929Q40866158-D75D71BA-D0EF-4E3C-B195-48D7DABE645BQ41154650-CF17F789-3B0D-4DB6-BA76-5482E517081BQ41434481-46768B9E-A4F6-4E9A-80D7-D3333D5F0394Q41721233-FF00755F-6765-40EE-BF04-BAF2B774F553Q41918189-2005AF05-6DA1-480A-A475-F7987E589F46Q42068252-AC5F8135-2CD2-496B-B472-7CD058CD67A1Q42274162-BFE033B4-E4D7-4580-ABE4-3E720C2828BD
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paolo Dellabona
@ast
Paolo Dellabona
@en
Paolo Dellabona
@es
Paolo Dellabona
@nl
Paolo Dellabona
@sl
type
label
Paolo Dellabona
@ast
Paolo Dellabona
@en
Paolo Dellabona
@es
Paolo Dellabona
@nl
Paolo Dellabona
@sl
prefLabel
Paolo Dellabona
@ast
Paolo Dellabona
@en
Paolo Dellabona
@es
Paolo Dellabona
@nl
Paolo Dellabona
@sl
P106
P1153
7003977918
P21
P31
P496
0000-0002-1414-633X